We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients (VITALITE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01007734
First Posted: November 4, 2009
Last Update Posted: July 27, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD.

Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Factors Determining Quality of Life Related to Respiratory Status According to Gender of COPD Patients Followed by a Pneumologist

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate with sufficient precision and according to gender the determining independent factors of quality of life related to respiratory status of patient with moderate to severe COPD

Enrollment: 449
Study Start Date: October 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First 3 consecutive adults with COPD with at least a three month follow up, seen by pneumologist
Criteria

Inclusion Criteria:

  • Adult patient who has a clinical visit for their usual follow-up.
  • patient with COPD with at least a three month follow up

Exclusion Criteria:

  • Current or history of asthma
  • Current participation in an interventional clinical study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01007734


  Show 185 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Alain Castaigne, Medical Director AstraZeneca
  More Information

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01007734     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2009/1
First Submitted: October 31, 2009
First Posted: November 4, 2009
Last Update Posted: July 27, 2010
Last Verified: July 2010

Keywords provided by AstraZeneca:
Quality of life
COPD patients
Evaluation According to Gender the Determining Independent Factors of Quality of Life Related to Respiratory Status of Patient With Moderate to Severe COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases